Table 1 Clinicopathologic features of CRC patients by tumor location
Characteristic | Total (n = 214) | Colon (n = 110) | Rectum (n = 104) |
|---|---|---|---|
Age (years) mean (range) | 60.35 (25–80) | 60.82 (25–80) | 59.80 (31–80) |
Gender | |||
Female | 74 (34.6%) | 42 (38.2%) | 32 (30.8%) |
Male | 140 (65.4%) | 68 (61.8%) | 72 (69.2%) |
Stage | |||
I/II | 52 (24.3%) | 24 (21.8%) | 28 (26.9%) |
III | 52 (24.3%) | 20 (18.2%) | 32 (30.8%) |
IV | 108 (50.5%) | 64 (58.2%) | 44 (42.3%) |
Unknown | 2 (0.9%) | 2 (1.8%) | – |
Tumor differentiation | |||
Well | 4 (1.9%) | 1 (0.9%) | 3 (2.9%) |
Moderate | 123 (57.5%) | 79 (71.8%) | 44 (42.3%) |
Poor | 5 (2.3%) | 4 (3.6%) | 1 (1.0%) |
Not assessable | 82 (38.3%) | 26 (23.6%) | 56 (53.8%) |
KRAS mutation status | |||
Wildtype | 116 (54.2%) | 60 (54.5%) | 56 (53.9%) |
Mutated | 84 (39.3%) | 46 (41.8%) | 38 (36.5%) |
Not available | 14 (6.5%) | 4 (3.6%) | 10 (9.6%) |
MSI | |||
MSI-H | 8 (3.7%) | 8 (7.3%) | 0 (0%) |
MSI-L/MSS | 206 (96.3%) | 102 (92.7%) | 104 (100%) |
CIMP | |||
CIMP-positive | 18 (8.5%) | 6 (5.6%) | 12 (11.5%) |
CIMP-negative | 193 (91.5%) | 101 (94.4%) | 92 (88.5%) |
Neoadjuvant treatment | |||
Yes | 69 (32.2%) | 16 (14.5%) | 53 (51.0%) |
No | 145 (67.8%) | 94 (85.5%) | 51 (49.0%) |
Adjuvant treatment | |||
Yes | 171 (80.0%) | 89 (80.9%) | 82 (78.8%) |
No | 45 (20.0%) | 21 (19.1%) | 22 (21.2%) |